The application of contemporary cardiovascular treatments and management strategies to hypertrophic cardiomyopathy (HCM) over the last decade have altered the natural history and course of this genetic heart disease, now providing the vast majority of at-risk HCM patients the reasonable expectation for extended (if not normal) longevity and excellent quality of life.
↧